Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecularly Guided Off-Label Anti-Cancer Drug Trial
2018-004623-36Phase 2Terminated
- Sponsor
- Akademiska sjukhuset
- Start
- Oct 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, cobimetinib, niraparib and everolimus in Nonhematologic neoplasms, hematopoietic malignancies and cancer, sponsored by Akademiska sjukhuset. Primary endpoint: Objective tumor response by cohort. Started Oct 2019; status: terminated.
02
Drugs
atezolizumabcobimetinibniraparibeverolimus
03
Conditions
Nonhematologic neoplasmshematopoietic malignanciescancer
Beyond the preview
Go deeper on 2018-004623-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004623-36.